The National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) encourage grant applications for translational research projects in muscular dystrophy.*
Several emerging pathways to treat muscular dystrophy show promise, ranging from palliative therapies that can markedly delay onset or progression of the disease to genetic or stem cell approaches that may reverse or eliminate the condition.
Potential research areas of interest include, but are not limited to, studies to: develop drug-based therapies to protect muscle mass; develop strategies to enhance existing muscle repair mechanisms; optimize cell-based muscle replacement strategies; develop, test, and improve strategies for gene replacement therapy; develop and test genetic modification therapies to bypass inherited mutations; and develop combination therapies that rely upon more than one of the strategies listed above in order to produce a more effective treatment than may be possible with any single strategy.
For more information, potential applicants should contact Dr. John Porter, Program Director, Channels, Synapses, and Circuits Cluster, NINDS, Neuroscience Center, 6001 Executive Boulevard, Room 2142, Bethesda, MD 20892; telephone: 301-496-1917; fax: 301-402-1501; e-mail: email@example.com.
*For a more detailed description of this announcement, please visit the NIH web site at: http://grants.nih.gov/grants/guide/pa-files/PAR-06-044.html.